Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen

被引：11

作者：

Badiou, S ^{[1
]}

De Boever, CM

Dupuy, AM

Baillat, V

Cristol, JP

Reynes, J

机构：

[1] Univ Hosp, Dept Biochem, F-34295 Montpellier, France

[2] Univ Hosp, Dept Infect Dis, F-34295 Montpellier, France

来源：

AIDS | 2003年 / 17卷 / 05期

关键词：

D O I：

10.1097/00002030-200303280-00023

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In order to characterize the influence of a lopinavir/ritonavir-containing regimen on the lipoprotein profile, lipid parameters and LDL size, as an index of atherogenicity, were determined in 24 HIV-infected adults before and after the initiation of lopinavir/ritonavir treatment. At baseline an abnormal prevalence of small dense LDL was observed. One month of lopinavir/ritonavir use enhanced triglyceride and apolipoprotein CIII levels and reduced LDL size, suggesting an increase in atherogenicity.

引用

收藏

页码：772 / 774

页数：3

相关论文

共 14 条

[1] Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients [J].

Benson, CA ;

Deeks, SG ;

Brun, SC ;

Gulick, RM ;

Eron, JJ ;

Kessler, HA ;

Murphy, RL ;

Hicks, C ;

King, M ;

Wheeler, D ;

Feinberg, J ;

Stryker, R ;

Sax, PE ;

Riddler, S ;

Thompson, M ;

Real, K ;

Hsu, A ;

Kempf, D ;

Japour, AJ ;

Sun, E .

JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (05) :599-607

[2] Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors:: Association with the development of lipodystrophy [J].

Bonnet, E ;

Ruidavets, JB ;

Tuech, J ;

Ferrières, J ;

Collet, X ;

Fauvel, J ;

Massip, P ;

Perret, B .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (01) :296-302

[3]

Chapman MJ, 1998, EUR HEART J, V19, pA24

[4] Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? [J].

Klein, D ;

Hurley, LB ;

Quesenberry, CP ;

Sidney, S .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 30 (05) :471-477

[5] A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients [J].

Lemieux, I ;

Laperrière, L ;

Dzavik, V ;

Tremblay, G ;

Bourgeois, J ;

Després, JP .

ATHEROSCLEROSIS, 2002, 162 (02) :363-371

[6]

LEPORT C, 2002, 9 C RETR OPP INF SEA

[7]

MURPHY RL, 2001, AIDS, V15, P1

[8] Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors [J].

Périard, D ;

Telenti, A ;

Sudre, P ;

Cheseaux, JJ ;

Halfon, P ;

Reymond, MJ ;

Marcovina, SM ;

Glauser, MP ;

Nicod, P ;

Darioli, R ;

Mooser, V .

CIRCULATION, 1999, 100 (07) :700-705

[9] Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy [J].

Schmitz, M ;

Michl, GM ;

Walli, R ;

Bogner, J ;

Bedynek, A ;

Seidel, D ;

Goebel, FD ;

Demant, T .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (03) :225-235

[10] Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease [J].

Seminari, E ;

Pan, A ;

Voltini, G ;

Carnevale, G ;

Maserati, R ;

Minoli, L ;

Meneghetti, G ;

Tinelli, C ;

Testa, S .

ATHEROSCLEROSIS, 2002, 162 (02) :433-438